Chong Kun Dang said Thursday that its U.S. partner, Cara Therapeutics, has received approval from the Food and Drug Administration for uremic pruritus treatment, CR-845.Chong Kun Dang participated in developing CR-845, branded as Korsuva, after gaining exclusive rights for domestic development and s
Korea’s obesity treatment market, which had been stagnant due to the Covid-19 outbreak, is regaining attention.According to IQVIA, a drug market research company, the size of the local obesity treatment market in the second quarter was 38.5 billion won ($32.9 million), up 2.9 percent from 37.6 billi
Celltrion said that it has started the clinical trial of a cocktail therapy of Regkirona, a Covid-19 antibody treatment, in the European Union. Cocktail therapy is a method of increasing efficacy by mixing two or more drugs.According to Clinical Trials, a clinical information site operated by the Na
About domestic 5,000 patients with neurofibromatosis type 1 (NF1) can now benefit from a new therapeutic option for treating the rare genetic disorder with the recent approval of AstraZeneca's Koselugo (ingredient: selumetinib), an expert said.Korean patients with NF1, which lacked a cure, had to re
The Hanmi Pharmaceutical Group has taken the first step toward becoming the vaccine hub of the Asia-Pacific region.According to industry insiders, Hanmi Science, the group's holding company, has recently submitted a proposal to the World Health Organization (WHO) to participate in the latter's proje
Botulinum toxin (BTX) maker Hugel said Wednesday that a consortium led by GS Group acquired the majority of the company's shares from Bain Capital's Leguh Issuer Designated Activity Company for 1.7 trillion won ($1.46 billion).Leguh Issuer Designated Activity Company, a U.S. investment firm, agreed
The government has been delaying discussing whether to allow reimbursement for Tecentriq (atezolizumab) due to concerns over increased health insurance costs.However, the arrival of Avastin’s biosimilar may accelerate talks for reimbursement for the combination therapy of Tecentriq and Avastin, indu
Kolmar Holdings said it would partner with the U.S. contract development and manufacturing organization (CDMO) Arranta Bio to develop KBL382, a candidate substance for treating inflammatory bowel disease.Under the accord, the two companies will cooperate on overall matters to develop and manufacture
Korea Pharma said Wednesday that it has signed a deal with a U.K. pharmaceutical company, Shield Therapeutics, to exclusively supply the latter's oral iron deficiency anemia therapy Accrufer (ingredient: ferric maltol) in Korea.Accrufer received approval from the U.S. Food and Drug Administration an
GlaxoSmithKline (GSK) said it selected Kwangdong Pharmaceutical, instead of SK Bioscience, to sell its quadrivalent influenza vaccine Fluatrix Tetra in Korea.On Tuesday, GSK said it signed an agreement with Kwangdong Pharmaceutical for a joint sale of Fluatrix Tetra.Fluarix Tetra added one more stra
Sanofi-Aventis Korea has updated the newly confirmed long-term safety data of Dupixent (ingredient: dupilumab) in treating adult patients with atopic dermatitis in Korea.The recent update was based on the confirmed safety profile up to three years of an open-label extension study conducted on 2,677
Medytox may have felt it worthwhile to file a lawsuit against Daewoong Pharmaceutical with the International Trade Commission (ITC) and nullify the ITC ban on Daewoong’s imports in a settlement with its U.S. partner Allergan and Daewoong’s partner Evolus.Medytox announced it would enter another lega
Vivozon said that it has resumed its phase 3b clinical trials for using Opiranserin, its non-narcotic analgesics, in treating bunionectomy.The company had temporarily halted the trial due to difficulties recruiting patients during the Covid-19 outbreak in the U.S. in August of last year. The company
The world needs Covid-19 treatments now more than ever due to the continuing increase of Covid-19 cases, but it will take a considerable time to commercialize Korea’s second Covid-19 treatment, industry watchers said.Among locally developed Covid-19 treatments, Celltrion’s Regkirona (ingredient: reg
Abion revealed its growth strategies and future plans in an online news conference on Monday ahead of its upcoming IPO in the Kosdaq market. “With our differentiated R&D strategies, Abion will achieve technology transfers through continuous studies,” CEO Shin Young-key said. “By going public on the
Pharmaceutical companies expanded their employment despite the prolonging Covid-19 pandemic in the first half of this year, data showed.Notably, the number of employees at companies providing contracted manufacturing service for Covid-19 vaccines, such as Samsung Biologics and SK Bioscience, increas
Natural substance-based medicines developed by local pharmaceutical companies showed sluggish sales in the first half of 2021 due to the Covid-19 pandemic and generic drug appearances.According to UBIST, a pharmaceutical research firm, among the six natural substance drugs --Joins, Motilitone, Still
Celltrion signed the contract to acquire the exclusive sales rights of Donerion Patch, a donepezil patch product to treat the Alzheimer’s, which the company has co-developed with Icure, on Friday.Celltrion has submitted a new drug application for the drug to the Ministry of Food and Drug Safety for
The government expanded health insurance benefits for immunotherapy Opdivo (nivolumab) and Yervoy (ipilimumab) to treat renal cancer, head and neck cancer, and Hodgkin lymphoma.Opdivo, a programmed death receptor-1 (PD-1) blocking antibody, and Yervoy, a CTLA-4 inhibitor, were developed by BMS and O
Open innovation has become a major strategy for Korean pharmaceutical companies to develop new drugs.They are increasingly going beyond the border to collaborate with foreign companies or research institutes for global open innovation.Teaming up with renowned foreign researchers could boost new drug